Baader Bank Aktiengesellschaft Sells 18,452 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Baader Bank Aktiengesellschaft decreased its position in Hims & Hers Health, Inc. (NYSE:HIMS) by 55.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,000 shares of the company’s stock after selling 18,452 shares during the quarter. Baader Bank Aktiengesellschaft’s holdings in Hims & Hers Health were worth $363,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Genesee Capital Advisors LLC acquired a new position in Hims & Hers Health in the 4th quarter valued at $889,000. Perigon Wealth Management LLC bought a new stake in Hims & Hers Health during the fourth quarter valued at about $337,000. Pacer Advisors Inc. acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at about $374,000. KBC Group NV increased its stake in shares of Hims & Hers Health by 107.9% in the fourth quarter. KBC Group NV now owns 8,471 shares of the company’s stock worth $205,000 after purchasing an additional 4,396 shares during the period. Finally, Raleigh Capital Management Inc. lifted its position in shares of Hims & Hers Health by 1,100.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 1,100 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $33.89 on Friday. The business’s fifty day moving average price is $28.96 and its two-hundred day moving average price is $22.47. Hims & Hers Health, Inc. has a fifty-two week low of $8.51 and a fifty-two week high of $35.02. The stock has a market capitalization of $7.40 billion, a price-to-earnings ratio of 77.01 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million for the quarter, compared to analyst estimates of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The company’s revenue for the quarter was up 77.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.04) earnings per share. Research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the transaction, the insider now owns 184,947 shares in the company, valued at $6,206,821.32. The trade was a 1.10 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Patrick Harrison Carroll sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $22.07, for a total value of $331,050.00. Following the transaction, the insider now directly owns 196,941 shares in the company, valued at approximately $4,346,487.87. This represents a 7.08 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,256,067 shares of company stock valued at $34,459,485. 17.71% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of analysts have issued reports on HIMS shares. Citigroup lowered Hims & Hers Health from a “neutral” rating to a “sell” rating and raised their target price for the company from $24.00 to $25.00 in a report on Friday, January 10th. BTIG Research initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Canaccord Genuity Group increased their price target on shares of Hims & Hers Health from $28.00 to $38.00 and gave the company a “buy” rating in a report on Monday, December 2nd. Deutsche Bank Aktiengesellschaft boosted their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Finally, Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and reduced their target price for the company from $32.00 to $18.00 in a research note on Thursday, November 14th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.